Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence Corey

Showing results (491-500 of 551) with videos related to

Pageof 56
Sort By:
The Journal of Clinical Investigation|October 8, 2019
Antibody Fc effector functions and IgG3 associate with decreased HIV-1 riskScott D Neidich, Youyi Fong, Shuying S Li, et al.
Medrxiv : the Preprint Server for Health Sciences|June 5, 2026
A phase 1 randomized controlled trial to evaluate the safety and immunogenicity of a HIV monomeric gp120 protein B-cell lineage targeting HIV vaccine in healthy adultsJames J Kobie, Wilton B Williams, William O Hahn, et al.
Plos Medicine|March 19, 2024
Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trialZoe Moodie, Erica Andersen-Nissen, Nicole Grunenberg, et al.
Nature Communications|March 23, 2024
Author Correction: High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trialsDaniel B Reeves, Bryan T Mayer, Allan C deCamp, et al.
Nature Communications|December 14, 2023
High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trialsDaniel B Reeves, Bryan T Mayer, Allan C deCamp, et al.
Eclinicalmedicine|November 8, 2023
Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country studyGustavo H Dayan, Nadine Rouphael, Stephen R Walsh, et al.
Nature Communications|May 25, 2026
Long-read deep sequencing reveals high rates of multilineage transmission and rapid viral population changes in acute HIV infectionJames I Mullins, Wenjie Deng, Elena E Giorgi, et al.
Medrxiv : the Preprint Server for Health Sciences|April 2, 2024
A HIV-1 Gp41 Peptide-Liposome Vaccine Elicits Neutralizing Epitope-Targeted Antibody Responses in Healthy IndividualsNathan B Erdmann, Wilton B Williams, Stephen R Walsh, et al.
Annals of the New York Academy of Sciences|January 14, 2022
Innovative vaccine approaches-a Keystone Symposia reportJennifer Cable, Rino Rappuoli, Elizabeth J Klemm, et al.
Nature Medicine|March 2, 2011
Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trialMorgane Rolland, Sodsai Tovanabutra, Allan C deCamp, et al.
Pageof 56

Showing results (491-500 of 551) with videos related to

Sort By:
Pageof 56
The Journal of Clinical Investigation|October 8, 2019
Antibody Fc effector functions and IgG3 associate with decreased HIV-1 riskScott D Neidich, Youyi Fong, Shuying S Li, et al.
Medrxiv : the Preprint Server for Health Sciences|June 5, 2026
A phase 1 randomized controlled trial to evaluate the safety and immunogenicity of a HIV monomeric gp120 protein B-cell lineage targeting HIV vaccine in healthy adultsJames J Kobie, Wilton B Williams, William O Hahn, et al.
Plos Medicine|March 19, 2024
Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trialZoe Moodie, Erica Andersen-Nissen, Nicole Grunenberg, et al.
Nature Communications|March 23, 2024
Author Correction: High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trialsDaniel B Reeves, Bryan T Mayer, Allan C deCamp, et al.
Nature Communications|December 14, 2023
High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trialsDaniel B Reeves, Bryan T Mayer, Allan C deCamp, et al.
Eclinicalmedicine|November 8, 2023
Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country studyGustavo H Dayan, Nadine Rouphael, Stephen R Walsh, et al.
Nature Communications|May 25, 2026
Long-read deep sequencing reveals high rates of multilineage transmission and rapid viral population changes in acute HIV infectionJames I Mullins, Wenjie Deng, Elena E Giorgi, et al.
Medrxiv : the Preprint Server for Health Sciences|April 2, 2024
A HIV-1 Gp41 Peptide-Liposome Vaccine Elicits Neutralizing Epitope-Targeted Antibody Responses in Healthy IndividualsNathan B Erdmann, Wilton B Williams, Stephen R Walsh, et al.
Annals of the New York Academy of Sciences|January 14, 2022
Innovative vaccine approaches-a Keystone Symposia reportJennifer Cable, Rino Rappuoli, Elizabeth J Klemm, et al.
Nature Medicine|March 2, 2011
Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trialMorgane Rolland, Sodsai Tovanabutra, Allan C deCamp, et al.
Pageof 56